Prostanoid signaling: Dual role for prostaglandin E2 in neurotoxicity

NeuroToxicology

Volumn 32, Issue 3, 2011, Pages 312-319

  Milatovic, Dejan ^a   Montine, Thomas J ^b   Aschner, Michael ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; E Prostanoid receptor; Neuroinflammation; Neurotoxicity; Prostaglandin E2

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

BRAIN INJURY; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; DINOPROSTONE; HUMANS; MODELS, ANIMAL; NEUROTOXICITY SYNDROMES; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION;

EID: 79953065448     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.02.004     Document Type: Review

References (152)

1. Abe T., Kunz A., Shimamura M., Zhou P., Anrather J., Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 2009, 29:66-72.
2. Abramovitz M., Boie Y., Nguyen T., Rushmore T.H., Bayne M.A., Metters K.M., et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 1994, 269:2632-2636.
3. Adreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010, 91:104-112.
4. Ahmad A.S., Zhuang H., Echeverria V., Doré S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 2006, 23:1895-1903.
5. Ahmad M., Ahmad A.S., Zhuang H., Maruyama T., Narumiya S., Dore S. Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmunol 2007, 184:172-179.
6. Akaike A., Kaneko S., Tamura Y., Nakata N., Shiomi H., Ushikubi F., et al. Prostaglandin E2 protects cultured cortical neurons against N-methyl-d aspartate receptor mediated glutamate cytotoxicity. Brain Res 1994, 663:237-243.
7. Akira S. Toll-like receptor signaling. J Biol Chem 2003, 278:38105-38108.
8. Aktan S., Aykut C., Ercan S. Leukotriene C4 and prostaglandin E2 activities in the serum and cerebrospinal fluid during acute cerebral ischemia. Prostaglandins Leukot Essent Fatty Acids 1991, 43:247-249.
9. Almer G., Teismann P., Stevic Z., Halaschek-Wiener J., Deecke L., Kostic V., et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002, 58:1277-1279.
10. Andrade da Costa B.L., Kang K.D., Rittenhouse K.D., Osborne N.N. The localization of PGE2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost. Neurochem Int 2009, 55:199-207.
11. Baran H., Heldt R., Hertting G. Increased prostaglandin formation in rat brain following systemic application of kainic acid. Brain Res 1987, 404:107-112.
12. Basu S., Mutschler D.K., Larsson A.O., Kiiski R., Nordgren A., Eriksson M.B. Propofol (Diprivan-EDTA) counteracts oxidative injury and deterioration of the arterial oxygen tension during experimental septic shock. Resuscitation 2001, 50:341-348.
13. Basu S., Whiteman M., Mattey D.L., Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis 2001, 60:627-631.
14. Basu S., Liu X., Nozari A., Rubertsson S., Miclescu A., Wiklund L. Evidence for time-dependent maximum increase of free radical damage and eicosanoid formation in the brain as related to duration of cardiac arrest and cardio-pulmonary resuscitation. Free Radic Res 2003, 37:251-256.
15. Bentzer P., Mattiasson G., McIntosh T.K., Wieloch T., Grande PO Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume. J Neurotrauma 2001, 18:275-285.
16. Bentzer P., Venturoli D., Carlsson O., Grände P.O. Low-dose prostacyclin improves cortical perfusion following experimental brain injury in the rat. J Neurotrauma 2003, 20:447-461.
17. Berridge M.J., Irvine R.F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984, 312:315-321.
18. Bhattacharya M., Peri K., Almazan G., Ribeiro-da-Silva A., Shichi H., Durocher Y., et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998, 95. 15792-15727.
19. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 2004, 56:240-248.
20. Bilson H.A., Mitchell D.L., Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett 2004, 572:271-275.
21. Boie Y., Sawyer N., Slipetz D.M., Metters K.M., Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995, 270:18910-18916.
22. Boillee S., Yamanaka K., Lobsiger S.C., Copeland N.G., Jenkins N.A., Kassiotis G., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
23. Bonventre J.V. The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol 1999, 10:404-412.
24. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004, 36:1187-1205.
25. Breyer M.D., Breyer R.M. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000, 9:23-29.
26. Breyer M.D., Breyer R.M. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001, 63:579-605.
27. Breyer R.M., Bagdassarian C.K., Myers S.A., Breyer M.D. Prostanoid receptors: subtypes and signaling. Ann Rev Pharmacol Toxicol 2001, 41:661-690.
28. Burks S.R., Wright C.L., McCarthy M.M. Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience 2007, 146:1117-1127.
29. Caggiano A.O., Kraig R.P. Rostaglandin E2 and 4-aminopyridine prevent the lipopolysaccharide-induced outwardly rectifying potassium current and interleukin-1beta production in cultured rat microglia. J Neurochem 1998, 70:2357-2368.
30. Carlson N.G., Rojas M.A., Black J.D., Redd J.W., Hille J., Hill K.E., et al. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation 2009, 17(6):5.
31. Carrasco E., Casper D., Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res 2007, 85:3109-3117.
32. Cimino P.J., Keene D., Breyer R.M., Montine K.S., Montine T.J. Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem 2008, 15:1863-1869.
33. Coleman R.A., Sheldrick R.L. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol 1989, 96:688-692.
34. Combrinck M., Williams J., De Berardinis M.A., Warden D., Puopolo M., Smith A.D., et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006, 77:85-88.
35. Couzin J. Drug safety. FDA panel urges caution on many antiinflammatory drugs. Science 2005, 307:1183-1185.
36. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006, 60:22-31.
37. Davis R.J., Murdoch C.E., Ali M., Purbrick S., Ravid R., Baxter G.S., et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 2004, 141:580-585.
38. de Menezes G.B., dos Reis W.G., Santos J.M., Duarte I.D., de Francischi J.N. Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration. Inflammation 2005, 29(4-6):163-169.
39. Dey I., Lejeune M., Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 2006, 149(6):611-623.
40. Di Giorgio F.D., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007, 10:608-614.
41. Dogne J.M., de Leval X., Hanson J., Frederich M., Lambermont B., Ghuysen A., et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004, 11:1223-1241.
42. Dogné J.M., Hanson J., Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005, 26:639-644.
43. Emery D.L., Djokic T.D., Graf P.D., Nadel J.A. Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 1989, 67:959-962.
44. Feldman M., McMahon A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?. Ann Int Med 2000, 132:134-143.
45. Fiebich B.L., Schleicher S., Spleiss O., Czygan M., Hull M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J Neurochem 2001, 79:950-958.
46. Fish J.E., Jameson L.S., Albright A., Norman P.S. Modulation of the bronchomotor effects of chemical mediators by prostaglandin F2 alpha in asthmatic subjects. Am Rev Respir Dis 1984, 130:571-574.
47. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003, 2:879-890.
48. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001, 345:433-442.
49. Fujitani Y., Kanaoka Y., Aritake K., Uodome N., Okazaki-Hatake K., Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002, 168:443-449.
50. Gao H., Peng B., Welch W.J., Wilcox C.S. Central thromboxane receptors: mRNA expression and mediation of pressor responses. Am J Physiol 1997, 272:R1493-R1500.
51. Giannarelli C., Zafar M.U., Badimon J.J. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?. Thromb Haemost 2010, 104:949-954.
52. Giles H., Leff P. The biology and pharmacology of PGD2. Prostaglandins 1988, 35:277-300.
53. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698-701.
54. Golovko M.Y., Murphy E.J. An improved LC-MS/MS procedure for brain prostanoid analysis using brain fixation with head-focused microwave irradiation and liquid-liquid extraction. J Lipid Res 2008, 49:893-902.
55. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008, 31(4):891-901.
56. Grande P.O., Möller A.D., Nordström C.H., Ungerstedt U. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiol Scand 2000, 44:886-894.
57. Griffin D.E., Wesselingh S.L., McArthur J.C. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994, 35:592-597.
58. Hao C.M., Breyer M.D. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 2007, 71:1105-1115.
59. Hao C.M., Breyer M.D. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008, 70:357-377.
60. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144-150.
61. Hasegawa H., Negishi M., Ichikawa A. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J Biol Chem 1996, 271:1857-1860.
62. Hata A.N., Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147-166.
63. He T., Lu T., d'Uscio L.V., Lam C.F., Lee H.C., Katusic Z.S. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 2008, 103:80-88.
64. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta 1996, 1299:125-140.
65. Hirai H., Tanaka K., Yoshie O., Ogawa K., Kenmotsu K., Takamori Y., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193:255-261.
66. Hirata M., Kakizuka A., Aizawa M., Ushikubi F., Narumiya S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 1994, 91:11192-11196.
67. Honda A., Sugimoto Y., Namba T., Watabe A., Irie A., Negishi M., et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem 1993, 268:7759-7762.
68. Huang Z.L., Urade Y., Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007, 7:33-38.
69. Hutchinson A.J., Chou C.L., Israel D.D., Xu W., Regan J.W. Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem Int 2009, 54:439-446.
70. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003, 108:125-129.
71. Imler J.L., Hoffmann J.A. Toll receptors in innate immunity. Trends Cell Biol 2001, 11:304-311.
72. Insel P.A. Analgesic-antipyretic and anti-inflammatory agents and drugs in the treatment of gout. Godman and Gilman's the pharmacological basis of therapeutics 1996, 617-657. McGraw-Hill, New York. J.G. Hardman, L.E. Limbird (Eds.).
73. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 2007, 4:2.
74. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12:225-229.
75. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res 2008, 1193:153-161.
76. Kong D.L., Prough D.S., Whitley J.M., Taylor C., Vines S., Deal D.D., et al. Hemorrhage and intracranial hypertension in combination in cerebral production of thromboxane A2. Crit Care Med 1991, 19:532-538.
77. Kudo I., Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002, 68-69:3-58.
78. Lai J., Jin H., Yang R., Winer J., Li W., Yen R., et al. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 1996, 271:H2197-H2208.
79. Legler D.F., Bruckner M., Uetz-von Allmen E., Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 2010, 42(2):198-201.
80. Leuner B., Falduto J., Shors T.J. Associative memory formation increases the observation of dendritic spines in the hippocampus. J Neurosci 2003, 23:659-6665.
81. Lewis R.A., Soter N.A., Diamond P.T., Austen K.F., Oates J.A., Roberts L.J. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982, 129:1627-1631.
82. Liang X., Wu L., Hand T., Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 2005, 92:477-486.
83. Liang X., Wang Q., Hand T., Wu L., Breyer R.M., Montine T.J., et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005, 25:10180-10187.
84. Liang X., Wang Q., Shi J., Lokteva L., Breyer R.M., Montine T.J., Andreasson K. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008, 64:304-314.
85. Liu D., Wu L., Breyer R., Mattson M.P., Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 2005, 57:758-761.
86. Lundblad C., Grände P.O., Bentzer P. Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin. J Cereb Blood Flow Metab 2008, 28:367-376.
87. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004, 24:257-268.
88. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10:S3-7.
89. McGeer E.G., McGeer P.L. Abeta immunotherapy and other means to remove amyloid. Curr Drug Targets CNS Neurol Disord 2005, 4(5):569-573.
90. Meja K.K., Barnes P.J., Giembycz M.A. Characterization of the prostanoid receptor (s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997, 122:149-157.
91. Miggin S.M., Kinsella B.T. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998, 1425:543-559.
92. Milatovic D., Aschner M. Measurement of isoprostanes as markers of oxidative stress in neuronal tissue. Curr Protocols Toxicol 2009, 12(14):1-12.
93. Milatovic D., Zaja-Milatovic S., Montine K.S., Horner P.J., Montine T.J. Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem 2003, 87:1518-1526.
94. Milatovic D., Milatovic S., Montine K., Shie F.S., Montine T.J. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immunity response in vivo. J Neuroinflammation 2004, 1:20.
95. Milatovic D., Zaja-Milatovic S., Montine K.S., Nivison M., Montine T.J. CD14-dependent innate immunity-mediated neuronal damage in vivo is suppressed by NSAIDs and ablation of a prostaglandin E2 receptor EP2. Curr Med Chem - Central Nervous System Agents 2005, 5:151-156.
96. Milatovic D., Montine T.J., Zaja-Milatovic S., Madison J.D., Bowman A., Aschner M. Morphometric analysis in neurodegenerative disease. Curr Protocols Toxicol 2010, 12(16):1-14. unit.
97. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
98. Minghetti L., Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem 1995, 65:2690-2698.
99. Minghetti L., Nicolini A., Polazzi E., Créminon C., Maclouf J., Levi G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997, 19:152-160.
100. Mizoguchi N., Eguchi N.K., Kimura K.Y., Kiyohara Y., Qu W.M., Huang Z.L., et al. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 2001, 98:11674-11679.
101. Mohri I., Taniike M., Taniguchi H., Kanekiyo T., Aritake K., Inui T., et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci 2006, 26:4383-4393.
102. Montine T.J., Sidell K.R., Crews B.C., Markesbery W.R., Marnett L.J., Roberts L.J., Morrow J.D., et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999, 53:1495-1498.
103. Montine T.J., Milatovic D., Gupta R.C., Valyi-Nagy T., Morrow J.D., Breyer R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 2002, 83:463-470.
104. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997, 36:1-21.
105. Murakami Y., Yokotani K., Okuma Y., Osumi Y. Thromboxane A2 is involved in the nitric oxide-induced central activation of adrenomedullary outflow in rats. Neuroscience 1998, 87:197-205.
106. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
107. Murata T., Lin M.I., Aritake K., Matsumoto S., Narumiya S., Ozaki H., et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci USA 2008, 105(50):20009-20014.
108. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007, 10:615-622.
109. Nakamura K., Kaneko T., Yamashita Y., Hasegawa H., Katoh H., Negishi M. Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J Comp Neurol 2000, 421:543-569.
110. Nakamura K., Li Y.Q., Kaneko T., Katoh H., Negishi M. Prostaglandin EP3 receptor protein in serotonin and catecholamine cell groups: a double immunofluorescence study in the rat brain. Neuroscience 2001, 103:763-775.
111. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25-30.
112. Narumiya S., Toda N. Different responsiveness of prostaglandin D2-sensitive systems to prostaglandin D2 and its analogues. Br J Pharmacol 1985, 85:367-375.
113. Narumiya S., Ogorochi T., Nakao K., Hayaishi O. Prostaglandin D2 in rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci 1982, 31:2093-2103.
114. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999, 79:1193-1226.
115. Oka T., Oka K., Schammell T.E., Lee C., Kelly J.F., Nantel F., et al. Relationship of EP(1-4) prostaglandin receptors with rat hypothalamic cell groups involved in lipopolysaccharide fever responses. J Comp Neurol 2000, 428:20-32.
116. Onoe H., Ueno R., Fujita I., Nishino H., Oomura Y., Hayaishi O. Prostaglandin D2, a cerebral sleep-inducing substance in monkeys. Proc Natl Acad Sci USA 1988, 85:4082-4086.
117. Pratico D., Lawson J.A., Rokach J., FitzGerald G.A. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001, 12:243-247.
118. Roberts M.F. Phospholipases: structural and functional motifs for working at an interface. FASEB J 1996, 10:1159-1172.
119. Rocha P.N., Plumb T.J., Coffman T.M. Eicosanoids: lipid mediators of inflammation in transplantation. Springer Semin Immunopathol 2003, 25:215-227.
120. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000, 403:103-108.
121. Sandig H., Pease J.E., Sabroe I. Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. J Leukoc Biol 2007, 81:372-382.
122. Santhanam A.V., Smith L.A., Katusic Z.S. Brain-derived neurotrophic factor stimulates production of prostacyclin in cerebral arteries. Stroke 2010, 41:350-356.
123. Sapirstein A., Bonventre J.V. Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim Biophys Acta 2000, 1488:139-148.
124. Sawyer N., Cauchon E., Chateauneuf A., Cruz R.P., Nicholson D.W., Metters K.M., et al. Molecular pharmacology of the human prostaglandin D(2) receptor, CRTH2. Br J Pharmacol 2002, 137:1163-1172.
125. Schuligoi R., Sturm E., Luschnig P., Konya V., Philipose S., Sedej M., et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 2010, 85:372-382.
126. Shenker A., Goldsmith P., Unson C.G., Spiegel A.M. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991, 266:9309-9313.
127. Shi J., Johansson J., Woodling N.S., Wang Q., Montine T.J., Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010, 184(12):7207-7218.
128. Shie F.S., Montine K.S., Breyer R.M., Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005, 52:70-77.
129. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387-437.
130. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992, 263:F181-F191.
131. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001, 107:1491-1495.
132. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
133. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J Lipid Res 2009, 50:S423-S428.
134. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., et al. 15-Deoxy-Δ 12,14-prostaglandin J2 inhibits multiple steps in the NF-κ B signaling pathway. Proc Natl Acad Sci USA 2000, 97:4844-4849.
135. Sugimoto Y., Shigemoto R., Namba T., Negishi M., Mizuno N., Narumiya S., et al. Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience 1994, 62:919-928.
136. Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997, 277:681-683.
137. Takadera T., Shiraishi Y., Ohyashiki T. Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int 2004, 45:713-719.
138. Tang D.G., Grossi I.M., Tang K.Q., Diglio C.A., Honn K.V. Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer 1995, 60:418-425.
139. Trivedi S.G., Newson J., Rajakariar R., Jacques T.S., Hannon R., KanaokaY, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci USA 2006, 103:5179-5184.
140. Vane J.R., Botting R.M. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995, 75:3A-10A.
141. Vanhoutte P.M., Feletou M., Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005, 144:449-458.
142. Walch L., de Montpreville V., Brink C., Norel X. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol 2001, 134:1671-1678.
143. Watanabe T., Nakao A., Emerling D., Hashimoto Y., Tsukamoto K., Horie Y., et al. Prostaglandin F2 alpha enhances tyrosine phosphorylation and DNA synthesis through phospholipase C-coupled receptor via Ca(2+)-dependent intracellular pathway in NIH-3T3 cells. J Biol Chem 1994, 269:17619-17625.
144. Woltjer R.L., McMahan W., Milatovic D., Kjerulf J.D., Shie F.S., Rung L.G., et al. Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. Neurobiol Dis 2007, 25:427-437.
145. Wright D.H., Ford-Hutchinson A.W., Chadee K., Metters K.M. The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br J Pharmacol 2000, 131:1537-1545.
146. Xie Z., Wei M., Morgan T.E., Fabrizio P., Han D., Finch C.E., et al. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci 2002, 22:3484-3492.
147. Yalcin M., Cavun S., Yilmaz M.S., Cengiz F., Savci V. Involvement of brain thromboxane A2 in hypotension induced by haemorrhage in rats. Clin Exp Pharmacol Physiol 2005, 32:960-967.
148. Yalcin M., Cavun S., Yilmaz M.S., Savci V. The involvement of central cholinergic system in the pressor effect of intracerebroventricularly injected U-46619, a thromboxane A2 analog, in conscious normotensive rats. Naunyn Schmiedebergs Arch Pharmacol 2005, 372:31-40.
149. Yoshikawa K., Kita Y., Kishimoto K., Shimizu T. Profiling of eicosanoid production in the rat hippocampus during kainate-induced seizure: dual-phase regulation and differential involvement of COX-1 and COX-2. J Biol Chem 2006, 26:14663-14669.
150. Zhang J., Rivest S. Anti-inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating lipopolysaccharide. J Neurochem 2001, 76:855-864.
151. Zhang J., Rivest S., Distribution regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur J Neurosci 1999, 11:2651-2668.
152. Zhang M., Song P., Xu J., Zou M.H. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase arterioscler. Thromb Vasc Biol 2010, 31:125-132.